Latest Conference

Anita Clayton, MD, explains how anhedonia points to past trauma and to future suicide and relapse risk, and how clinicians can screen for it quickly.

Christoph Correll, MD, explains why asking "How many doses have you missed?" works better than "Are you taking your medication?" and how to address the reasons behind missed doses.

An esketamine expert reflects on 7 years of nasal spray use and asks why racemic ketamine faces none of the same rules.

Explore tailored MDD augmentation strategies, balancing antipsychotic side effects, cautious dosing in older adults, and when to consider ketamine after partial response.

Why psychiatry might miss daytime sleepiness; assess sleep debt, scale scores, and sedating meds, deprescribe wisely, and rule out sleep apnea before stimulants.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.

Real-world data show Lybalvi cuts acute care visits in schizophrenia or bipolar I with AUD, while long-acting aripiprazole offers flexible dosing and stable symptom control.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

New evidence links hippocampal “internally generated” activity to memory and psychosis, suggesting new network-based models for schizophrenia.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Explore how TMS might be useful in treating schizophrenia, and how researchers are working to localize target areas.

Causal lesion and stimulation studies map psychosis to hippocampus–thalamus circuits, pointing to a reproducible TMS target for schizophrenia symptoms.

Adolescent synaptic pruning may fuel schizophrenia; researchers explore how restoring plasticity could ease fixed delusions.

Primate brain tissue studies track pruning, myelination, and dopamine across development, revealing adolescence-linked neural dynamics that may explain schizophrenia risk.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.

Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.

Brenipatide being investigated for alcohol use disorder, while exploring relapse prevention in recurrent depression and other psychiatric conditions.

Phase 1 brenipatide shows week-long exposure and tolerable GI effects, fueling studies in alcohol and other substance use disorders.

Learn how early antidepressant response guides faster treatment changes in major depression, with earlier use of esketamine, TMS, and ECT despite insurance barriers.

Learn how experts distinguish agitation from psychosis in Alzheimer disease, weigh new FDA options, and apply evidence for off-label care.

Three posters presented at APA 2026 detail real-world treatment patterns, pooled long-term cardiometabolic safety, and urinary adverse event rates with xanomeline and trospium chloride.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

How can new Alzheimer therapies benefit patients today?

Consensus definition clarifies Alzheimer agitation, reviews FDA-approved brexpiprazole and dextromethorphan-bupropion, and spotlights caregiver burden

Explore next-gen depression therapies targeting neuroplasticity and why biomarkers may unlock precision psychiatry for MDD.